Primaquine Dose in Pediatrics for Plasmodium vivax
For pediatric patients with P. vivax malaria and normal G6PD status, administer primaquine at 0.5 mg/kg/day for 14 days (total dose 7.0 mg/kg) following blood-stage treatment with chloroquine or an ACT.
Standard Dosing Regimen
The established pediatric primaquine dose is 0.3 mg/kg/day for 14 days 1, though this older guideline recommendation has been superseded by more recent evidence showing superior efficacy with higher total doses.
Current evidence strongly supports a total dose of 7.0 mg/kg over 14 days (0.5 mg/kg/day) rather than the older 3.5 mg/kg regimen 2. This higher-dose regimen demonstrated 86% recurrence-free survival at 6 months compared to only 58-59% with the lower 3.5 mg/kg dose 2. The most recent pediatric trial (2025) confirmed that 7.0 mg/kg total dose regimens were safe and significantly reduced P. vivax recurrence in children without G6PD deficiency 3.
Alternative Shortened Regimens
For adherence concerns in G6PD-normal children, 0.5 mg/kg/day for 7 days (total 3.5 mg/kg) may be considered, though this provides lower efficacy than the 14-day higher-dose regimen 3, 4, 5. The CHILDPRIM trial showed that both 7-day and 14-day schedules at 7.0 mg/kg total dose had comparable efficacy (79.4% vs 82.3% recurrence-free at 180 days), with the shorter regimen offering potential adherence advantages 3.
An ultra-short 1.0 mg/kg/day for 7 days (total 7.0 mg/kg) has been studied but may increase serious adverse events compared to the standard 14-day regimen 6, 7.
Critical G6PD Considerations
G6PD testing is mandatory before primaquine administration 8. The drug is absolutely contraindicated in:
- Severe G6PD deficiency
- Pregnancy (even if mother is G6PD-normal, fetus may be deficient) 8
- Breastfeeding infants who may be G6PD-deficient 8
Modified Dosing for G6PD Deficiency
In populations where severe G6PD deficiency is common (particularly Asian populations), primaquine should not be administered for greater than 5 days due to life-threatening hemolysis risk 1. For mild-to-moderate G6PD deficiency with non-Mediterranean variants (A-), weekly primaquine at 0.75 mg/kg (maximum 45 mg) for 8 weeks with close hemolysis monitoring may be considered 6, 9.
Safety Monitoring Requirements
Baseline hemoglobin and hematocrit must be checked before treatment, with close hematological monitoring at days 3 and 8 8. Discontinue primaquine immediately if:
- Darkening of urine occurs
- Marked fall in hemoglobin or erythrocyte count
- Signs of hemolytic anemia develop 8
The most common adverse events in children include methemoglobinemia, anemia, and gastrointestinal symptoms 3. Higher doses result in more adverse events but serious adverse events remain rare when G6PD-deficient patients are excluded 3.
Administration Timing
Primaquine should be administered concurrently with or immediately after chloroquine blood-stage therapy 10, 8, not delayed. The FDA label specifies concurrent administration to eradicate exoerythrocytic parasites 8.
Key Clinical Pitfalls
- Never prescribe primaquine without G6PD testing when testing is available 8
- Do not use the outdated 3.5 mg/kg total dose when 7.0 mg/kg is feasible—efficacy is substantially lower 2
- In Asian populations with unknown G6PD status, limit treatment to 5 days maximum 1
- Monitor for hemolysis even in G6PD-normal patients, as baseline testing has limitations 8
- Ensure adequate medical support is available to manage potential hemolytic complications 8